← All Century Therapeutics, INC filings

Century Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
IPSC
Century Therapeutics, INC
10-K: Century Therapeutics Narrows Losses, Secures Funding into 2029
Century Therapeutics reported a significant reduction in net loss for 2025, driven by collaboration revenue, and extended its cash runway into Q1 2029 with a recent private placement, while reprioritizing its cell therapy pipeline.
NASDAQ
IPSC
Century Therapeutics, INC
10-K: Century Therapeutics Announces 2024 Results, Pipeline Prioritization
Century Therapeutics reports its 2024 financial results and outlines a strategic shift in its preclinical pipeline, focusing on iT cell therapies.
NASDAQ
IPSC
Century Therapeutics, INC
10-K: Century Therapeutics and Fujifilm Cellular Dynamics Expand Collaboration with New Licensing Agreement
Century Therapeutics and Fujifilm Cellular Dynamics have entered into a new licensing agreement expanding their collaboration to include autoimmune and inflammatory diseases, alongside amendments to existing agreements.